摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[2[(dimethylamino)-sulfonylamino]ethyl]acetamide | 87484-95-5

中文名称
——
中文别名
——
英文名称
N-[2[(dimethylamino)-sulfonylamino]ethyl]acetamide
英文别名
N-{2-[(Dimethylsulfamoyl)amino]ethyl}acetamide;N-[2-(dimethylsulfamoylamino)ethyl]acetamide
N-[2[(dimethylamino)-sulfonylamino]ethyl]acetamide化学式
CAS
87484-95-5
化学式
C6H15N3O3S
mdl
MFCD24390544
分子量
209.269
InChiKey
ZRTRDGJHELLFBS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.226±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.4
  • 重原子数:
    13
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.833
  • 拓扑面积:
    86.9
  • 氢给体数:
    2
  • 氢受体数:
    5

SDS

SDS:e078a948937b4594513d7d23bd2070d2
查看

反应信息

  • 作为反应物:
    描述:
    N-[2[(dimethylamino)-sulfonylamino]ethyl]acetamide 生成 2-[N-[(dimethylamino)sulfonyl]amino]ethylamine hydrochloride
    参考文献:
    名称:
    ERHARDT, PAUL W.;MATIER, WILLIAM L.
    摘要:
    DOI:
  • 作为产物:
    参考文献:
    名称:
    Aromatic and esters of hydroxypropylamines
    摘要:
    通式为##STR1##的新化合物,其中Ar代表取代或未取代的芳香族或杂环基团;W代表1至约10个碳原子的烷基;B代表--NR.sub.2 COR.sub.1、--NR.sub.2 CONR.sub.1 R.sub.3、--NR.sub.2 SO.sub.2 R.sub.1、--NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3或--NR.sub.2 COOR.sub.1,其中R.sub.1、R.sub.2和R.sub.3可以相同也可以不同,可以是氢、烷基、烷氧基烷基、环烷基、烯基、炔基、芳基、杂芳基或芳基烷基,但当B为--NR.sub.2 SO.sub.2 R.sub.1或--NR.sub.2 COOR.sub.1时,R.sub.1不是氢,或者R.sub.1和R.sub.3可以与N一起形成5到7元杂环基团;以及其药学上可接受的盐。这些化合物具有β-肾上腺素受体阻滞活性,并且在青光眼的治疗中也很有用。
    公开号:
    US04582855A1
点击查看最新优质反应信息

文献信息

  • 2-hydroxypropylamine heteroaryl ester derivatives
    申请人:E. I. Du Pont de Nemours and Company
    公开号:US04798892A1
    公开(公告)日:1989-01-17
    The present invention relates to compounds of the general formula ##STR1## wherein Ar represents a substituted or unsubstituted heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR.sub.2 COR.sub.1, --NR.sub.2 CONR.sub.1 R.sub.3, --NR.sub.2 SO.sub.2 R.sub.1, NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3, or --NR.sub.2 COOR.sub.1, wherein R.sub.1, R.sub.2 and R.sub.3 may be alike or different and may be hydrogen, alkyl, alkoxyalkyl cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.1 is not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.1 or --NR.sub.2 COOR.sub.1, or R.sub.1 and R.sub.3 may together with N form a 5 to 7 membered heterocyclic group and the pharmaceutically acceptable salts thereof. The compounds exhibit beta-adrenergic blocking activity and are also useful in the treatment of glaucoma.
    本发明涉及一般式为##STR1##的化合物,其中Ar代表取代或未取代的杂环基团;W代表1至约10个碳原子的烷基;B代表--NR.sub.2 COR.sub.1,--NR.sub.2 CONR.sub.1 R.sub.3,--NR.sub.2 SO.sub.2 R.sub.1,NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3或--NR.sub.2 COOR.sub.1,其中R.sub.1,R.sub.2和R.sub.3可能相同也可能不同,可以是氢,烷基,烷氧基烷基,环烷基,烯基,炔基,芳基,杂芳基或芳基烷基,但当B为--NR.sub.2 SO.sub.2 R.sub.1或--NR.sub.2 COOR.sub.1时,R.sub.1不是氢,或者R.sub.1和R.sub.3可以与N一起形成5到7成员的杂环基团,以及其药用盐。这些化合物表现出β-肾上腺素受体阻滞活性,并且在青光眼的治疗中也很有用。
  • 2-hydroxypropylamine aryl ester derivatives and pharmaceutical use
    申请人:E. I. Du Pont de Nemours and Company
    公开号:US04935421A1
    公开(公告)日:1990-06-19
    Novel compounds of the general formula ##STR1## wherein Ar represents a substituted or unsubstituted aromatic or heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR.sub.2 COR.sub.1, --NR.sub.2 CONR.sub.1 R.sub.3, --NR.sub.2 SO.sub.2 R.sub.1, --NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3, or --NR.sub.2 COOR.sub.1 wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.1 is not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.1 or --NR.sub.2 COOR.sub.1, or R.sub.1 and R.sub.3 may together with N form a 5 to 7 membered heterocyclic group; and the pharmaceutically acceptable salts thereof. These compounds exhibit .beta.-adrenergic blocking activity and are also useful in the treatment of glaucoma.
    一般式为##STR1##的新化合物,其中Ar代表取代或未取代的芳香或杂环基;W代表1至约10个碳原子的烷基;B代表--NR.sub.2 COR.sub.1、--NR.sub.2 CONR.sub.1 R.sub.3、--NR.sub.2 SO.sub.2 R.sub.1、--NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3或--NR.sub.2 COOR.sub.1,其中R.sub.1、R.sub.2和R.sub.3可以相同或不同,可以是氢、烷基、烷氧基烷基、环烷基、烯基、炔基、芳基、杂芳基或芳基烷基,但当B为--NR.sub.2 SO.sub.2 R.sub.1或--NR.sub.2 COOR.sub.1时,R.sub.1不是氢,或者R.sub.1和R.sub.3可以与N一起形成5到7个成员的杂环基;以及其药学上可接受的盐。这些化合物表现出β-肾上腺素能阻断活性,并且在青光眼的治疗中也有用。
  • 2-hydroxypropylamine aryl ester derivatives
    申请人:E. I. du Pont de Nemours and Company
    公开号:US04810717A1
    公开(公告)日:1989-03-07
    Novel compounds of the general formula ##STR1## wherein Ar represents a substituted or unsubstituted aromatic or heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR.sub.2 COR.sub.1, --NR.sub.2 CONR.sub.1 R.sub.3, --NR.sub.2 SO.sub.2 R.sub.1, --NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3, or --NR.sub.2 COOR.sub.1 wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.1 is not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.1 or --NR.sub.2 COOR.sub.1, or R.sub.1 and R.sub.3 may together with N form a 5 to 7 membered heterocyclic group; and the pharmaceutically acceptable salts thereof. These compounds exhibit .beta.-adrenergic blocking activity and are also useful in the treatment of glaucoma.
    通式为##STR1##的新化合物,其中Ar代表取代或未取代的芳香或杂环基团;W代表1至约10个碳原子的烷基;B代表--NR.sub.2 COR.sub.1,--NR.sub.2 CONR.sub.1 R.sub.3,--NR.sub.2 SO.sub.2 R.sub.1,--NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3或--NR.sub.2 COOR.sub.1,其中R.sub.1,R.sub.2和R.sub.3可以相同或不同,可以是氢,烷基,烷氧基烷基,环烷基,烯基,炔基,芳基,杂芳基或芳基烷基,但当B为--NR.sub.2 SO.sub.2 R.sub.1或--NR.sub.2 COOR.sub.1时,R.sub.1不是氢,或R.sub.1和R.sub.3可以与N一起形成5到7个成员的杂环基团;以及其药学上可接受的盐。这些化合物表现出β-肾上腺素能阻滞活性,并且在青光眼的治疗中也有用。
  • ERHARDT, PAUL W.;MATIER, WILLIAM L.
    作者:ERHARDT, PAUL W.、MATIER, WILLIAM L.
    DOI:——
    日期:——
  • EP0093765A4
    申请人:——
    公开号:EP0093765A4
    公开(公告)日:1984-04-27
查看更多